$AURA
Aura Biosciences, Inc. Common Stock
XNAS•Health Care•Biological Products, (No Diagnostic Substances)
$6.27
▼-4.13%-$0.270
Subscriptions are live. Early access $24.99/mo, or start with 5 free premium days.
Plans & pricingDonateAura Biosciences, Inc. Common Stock
XNAS•Health Care•Biological Products, (No Diagnostic Substances)
Why is AURA down today? It is at $6.27 (-4.13%), and our scanner flagged it 74 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment AURA spikes, and full due diligence on AURA — key stats, earnings, dilution and insider activity. Free.
Our scanner flagged $AURA 74 times in the last 30 days. Create a free account to track $AURA, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
AURA is one of today's most active names, trading on unusually heavy volume (live price and day move above). Our scanner has fired 8 unusual-volume and momentum alerts on AURA today, peaking at 74.9x its normal volume.
Likely catalystAura Biosciences, Inc.: Q2 FY2026 results, three months to Jun 30, 2026, from an SEC filing. Read it →Latest filingSC 13GPassive 5%+ stake disclosedOct 1, 2026 · 11 days agoThe company can keep selling new shares into the market. Size not stated in the filing.
Some filings did not state a size, so these are floors.
At-the-market (ATM) offering active — the company can keep selling new shares into the market over time (ongoing)
49,899,650 new shares · At-the-market (ATM) program — sells new shares into the market gradually over time · About $75.0M in size · Priced at $6/share
Sources: float & market cap via Polygon · short interest via FINRA · borrow & shortability via Alpaca · SSR from Reg SHO 201 · filings & dilution via SEC EDGAR · analysts via Nasdaq.
Auto-generated from public data for research and education. Not investment advice.
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Abu-Absi Susan Officer | Acquired (grant/award) | +135K 0.1% of company | n/a | 135K | n/a | Sep 1, 26 |
Elazzouzi Amy Officer | Acquired (grant/award) | +24K 0.02% of company | added 20% | 144K | n/a | Sep 1, 26 |
Hopkins Janet Jill Officer | Acquired (grant/award) | +59K 0.06% of company | added 18% | 380K | n/a | Sep 1, 26 |
Kratz Erica Officer | Acquired (grant/award) | +101K 0.10% of company | n/a | 101K | n/a | Sep 1, 26 |
Person Julie Officer | Acquired (grant/award) | +108K 0.1% of company | n/a | 108K | n/a | Sep 1, 26 |
Bender Jeremy Director | Acquired (grant/award) | +30K 0.03% of company | n/a | 30K | n/a | Jul 7, 26 |
Kilroy Conor Officer | Acquired (grant/award) | +15K 0.01% of company | added 6.8% | 233K | n/a | Jul 1, 26 |
Gibney Anthony S Officer | Sold (automatic/other) | -13K 0.01% of company | sold 4.6% | 265K | $82K at $6.42 | Jun 16, 26 |
Mattessich Antony C. Director | Acquired (grant/award) | +15K 0.01% of company | added 64% | 39K | n/a | Jun 11, 26 |
Johnson David Michael Director | Acquired (grant/award) | +15K 0.01% of company | added 8.4% | 194K | n/a | Jun 11, 26 |
Srivastava Sapna Director | Acquired (grant/award) | +15K 0.01% of company | added 64% | 39K | n/a | Jun 11, 26 |
Bitetti Teresa Marie Director | Acquired (grant/award) | +15K 0.01% of company | added 71% | 36K | n/a | Jun 11, 26 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Blend of news sentiment, today’s move, and community votes. Not investment advice.
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
The tickers our scanner is lighting up most over the last 48 hours.
Comparable names in biological products, (no diagnostic substances), closest in size first.
AURA is one of today's most active names, trading on unusually heavy volume (live price and day move above). Our scanner has fired 8 unusual-volume and momentum alerts on AURA today, peaking at 74.9x its normal volume.
AURA last traded at $6.27, down 4.13% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
Aura Biosciences, Inc. Common Stock (AURA) is next expected to report earnings on Thursday, November 12, 2026, about 30 days away. Earnings reports often cause large overnight gaps, so many traders manage risk around the date. The date can shift until the company officially confirms it.
The AURA Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged AURA 74 times in the last 30 days.
AURA (Aura Biosciences, Inc. Common Stock) trades on XNAS, with a market cap of about $678M in the Biological Products, (No Diagnostic Substances) sector.
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge AURA for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.
$AURA discussion
Sign in to ask a question or join the discussion.